Match!
Kaatje Bollaerts
Katholieke Universiteit Leuven
Adverse effectImmunologyVaccinationMedicineEnvironmental health
34Publications
9H-index
215Citations
What is this?
Publications 38
Newest
#1Kaatje Bollaerts (Katholieke Universiteit Leuven)H-Index: 9
#2Alexandros Rekkas (Katholieke Universiteit Leuven)
Last. Rosa GiniH-Index: 20
view all 6 authors...
There is a strong and continuously growing interest in using large electronic healthcare databases to study health outcomes and the effects of pharmaceutical products. However, concerns regarding disease misclassification (i.e. classification errors of the disease status) and its impact on the study results are legitimate. Validation is therefore increasingly recognized as an essential component of database research. In this work, we elucidate the interrelations between the true prevalence of a ...
Source
#1Kaatje BollaertsH-Index: 9
#2Edouard LedentH-Index: 6
Last. Vincent BauchauH-Index: 8
view all 13 authors...
Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using electronic health record (eHR) databases in Europe. Proof-of-concept studies were designed to assess the proposed processes and system for generating the required evidence to perform B/R assessment and near-real time monitoring of vaccines. We aimed to test B/R methodologie...
1 CitationsSource
#1Rosa GiniH-Index: 20
#2Caitlin Dodd (UU: Utrecht University)H-Index: 1
view all 22 authors...
Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using European healthcare databases. Event misclassification can result in biased estimates. Using different algorithms for identifying cases of Bordetella pertussis (BorPer) infection as a test case, we aimed to describe a strategy to quantify event misclassification, when manua...
1 CitationsSource
#1Kaatje BollaertsH-Index: 9
#2Tom De SmedtH-Index: 2
Last. Vincent BauchauH-Index: 8
view all 14 authors...
Abstract Background The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private partnership aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using European electronic health record (eHR) databases. This proof-of-concept study aimed to test the feasibility of near real-time (NRT) monitoring of vaccination coverage, benefits and risks based on multiple European eHR databases, using acellular pertussis vaccination ...
1 CitationsSource
#1Myint Tin Tin Htar (Pfizer)H-Index: 4
#2Maria A. J. de Ridder (Erasmus University Medical Center)H-Index: 27
Last. Miriam Sturkenboom (Katholieke Universiteit Leuven)H-Index: 1
view all 20 authors...
Abstract The Accelerated Development of VAccine benefit-risk Collaboration in Europe (ADVANCE), a public-private consortium, implemented and tested a distributed network system for the generation of evidence on the benefits-risks of marketed vaccines in Europe. We tested the system by estimating the incidence rate (IR) of pertussis and pertussis-related complications in children vaccinated with acellular (aP) and whole-cell (wP) pertussis vaccine. Data from seven electronic databases from four c...
1 CitationsSource
#1Hanne-Dorthe EmborgH-Index: 23
#2Johnny Kahlert (Aarhus University Hospital)H-Index: 15
Last. Miriam Sturkenboom (Katholieke Universiteit Leuven)H-Index: 1
view all 16 authors...
© 2019 Introduction: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines, using existing healthcare databases in Europe. The objective of this paper was to assess the feasibility of using electronic healthcare databases to estimate dose-specific acellular pertussis (aP) and whole cell pertussis (wP) vaccine coverage. Methods: Seven electronic...
Source
#1Toon Braeye (University of Hasselt)H-Index: 4
#2Vincent BauchauH-Index: 8
Last. Kaatje Bollaerts (Katholieke Universiteit Leuven)H-Index: 9
view all 8 authors...
Introduction The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines, using existing electronic healthcare record (eHR) databases in Europe. Part of the data in such sources is missing due to incomplete follow-up hampering the accurate estimation of vaccination coverage. We compared different methods for coverage estimation from eHR databases; na...
Source
#1Kaatje Bollaerts (Katholieke Universiteit Leuven)H-Index: 9
#2Maria Alexandridou (Katholieke Universiteit Leuven)
Last. Thomas Verstraeten (Katholieke Universiteit Leuven)H-Index: 8
view all 3 authors...
Abstract Background The United Kingdom introduced routine vaccination with the live-attenuated zoster vaccine for 70 year-olds in 2013, with the vaccine also offered to 79 year-olds as part of a catch-up campaign. In the subsequent years, the catch-up campaign was extended to also include adults aged 78 years. We investigated 14 pre-identified potential risk factors for potential modified vaccine effectiveness. Methods This retrospective cohort study in England included subjects born in 1943–194...
Source
#1Kaatje Bollaerts (Katholieke Universiteit Leuven)H-Index: 9
#2Thomas Verstraeten (Katholieke Universiteit Leuven)H-Index: 8
Last. Catherine CohetH-Index: 10
view all 3 authors...
Abstract Introduction It has been suggested that some vaccines have effects beyond protection against the diseases they target, called non-specific effects (NSEs). In 2016, a systematic review by Higgins et al., commissioned by the WHO Strategic Advisory Group of Experts (SAGE) on immunization, estimated the relative risk (RR) of all-cause mortality after whole-cell Diphtheria-Tetanus-Pertussis (DTwP) vaccination to be 1.38 (95% CI: 0.92–2.08), and described these potential NSEs as inconsistent....
Source
1234